Gilead Sciences, Inc.GILDNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 77% recommend buying.

Consensus Rating

Buy

26 analysts·High coverage

77%

Rating Distribution

Strong Buy

00%

Buy

2077%

Hold

623%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case

$105.00

-30%

Consensus

$157.38

+5%

Bull Case

$177.00

+18%

Price Range26 analysts

Low

Consensus

High

$105.00

$177.00

Current Target

Current Price

$150.03

Upside to Target

$7.35

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$8.69(18 analysts)

P/E22x

Current: 21.7x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+6.26%

EPS+10.79%

FY2028

Rev+5.31%

EPS+8.94%

FY2029

Rev+6.11%

EPS+10.94%

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+7.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 19, 2026Barclays

Gilead initiated with an Equal Weight at Barclays

Target:$155.00

+2.6%from $151.12

Feb 19, 2026Mizuho Securities

Gilead price target raised to $170 from $140 at Mizuho

Target:$170.00

+11.3%from $152.74

Feb 18, 2026UBS

Gilead price target raised to $175 from $155 at UBS

Target:$175.00

+12.7%from $155.27

Feb 11, 2026Scotiabank

Gilead price target raised to $177 from $140 at Scotiabank

Target:$177.00

+14.0%from $155.29

Feb 11, 2026Bernstein

Gilead Sciences (GILD) PT Raised to $160 at Bernstein SocGen Group

Target:$160.00

+2.9%from $155.45

Feb 11, 2026Morgan Stanley

Gilead price target raised to $171 from $150 at Morgan Stanley

Target:$171.00

+9.8%from $155.72

Feb 11, 2026Truist Financial

Gilead Sciences (GILD) PT Raised to $162 at BofA Securities

Target:$162.00

+3.9%from $155.87

Feb 11, 2026Truist Financial

Gilead price target raised to $152 from $145 at Truist

Target:$152.00

-1.7%from $154.69

Feb 11, 2026Oppenheimer

Gilead price target raised to $165 from $128 at Oppenheimer

Target:$165.00

+7.5%from $153.46

Feb 11, 2026Cantor Fitzgerald

Gilead price target raised to $155 from $135 at Cantor Fitzgerald

Target:$155.00

+5.3%from $147.23

Feb 11, 2026Needham

Gilead Sciences (GILD) PT Raised to $170 at Needham

Target:$170.00

+10.3%from $154.09

Feb 11, 2026Robert W. Baird

Gilead price target raised to $145 from $108 at Baird

Target:$145.00

-5.8%from $153.89

Feb 11, 2026BMO Capital

Gilead price target raised to $160 from $150 at BMO Capital

Target:$160.00

+8.7%from $147.23

Feb 11, 2026Wells Fargo

Gilead price target raised to $165 from $150 at Wells Fargo

Target:$165.00

+12.1%from $147.23

Jan 27, 2026Truist Financial

Gilead price target raised to $145 from $140 at Truist

Target:$145.00

+4.1%from $139.23

Jan 26, 2026BMO Capital

Gilead Sciences (GILD) PT Raised to $150 at BMO Capital

Target:$150.00

+9.5%from $137.01

Jan 26, 2026UBS

Gilead price target raised to $155 from $145 at UBS

Target:$155.00

+13.8%from $136.16

Jan 13, 2026Morgan Stanley

Gilead price target lowered to $150 from $151 at Morgan Stanley

Target:$150.00

+22.7%from $122.25

Jan 7, 2026UBS

Gilead assumed with Buy from Neutral at UBS

Target:$145.00

+19.5%from $121.36

Dec 29, 2025Bernstein

Bernstein Reiterates Outperform Rating on Gilead Sciences (GILD)

Target:$135.00

+8.4%from $124.56

Dec 15, 2025Wolfe Research

Gilead Sciences (GILD) PT Raised to $150 at Wolfe Research

Target:$150.00

+24.6%from $120.41

Dec 12, 2025Morgan Stanley

Gilead price target raised to $151 from $147 at Morgan Stanley

Target:$151.00

+22.6%from $123.21

Dec 10, 2025HSBC

Gilead price target raised to $133 from $110 at HSBC

Target:$133.00

+11.4%from $119.36

Nov 25, 2025BMO Capital

BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)

Target:$135.00

+5.8%from $127.57

Nov 24, 2025Truist Financial

Gilead assumed with a Buy at Truist

Target:$140.00

+9.5%from $127.91

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance